AMLX_OUT_1 [2025-04-02 16:25:53 -0400] 2649 Bytes | 697 tokens | Cum: 697 tkns (8.71% of 8k)
==========================================================================

Turbo, you got one job - predict the hottest stocks of the day -- before everyone else does! Ha! So today we're looking at Amylyx Pharmaceuticals (AMLX) which is at 3.81 up from 3.34. So, I pulled together a bunch of data for you to look over real fast. It's still early, 4:25:52 PM on Wed Apr 02, 2025 -0400. So, what's the verdict? You're the expert!

--- COMPANY PROFILE ---
Company: Amylyx Pharmaceuticals (AMLX)
IPO: 2022-01-07 (3 Years Ago)
Market Cap: $298,590,317
Shares Outstanding: 88,600,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.

Here's the first list of news for Amylyx Pharmaceuticals:

C1 - Today 09:00AM - Amylyx Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
C2 - Mar-27-25 10:17AM - Is Amylyx Pharmaceuticals (AMLX) The Hot Biotech Stock Under $5?
C3 - Mar-05-25 10:01AM - Amylyx Pharmaceuticals Inc (AMLX) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ...
C4 - Mar-04-25 06:00AM - Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
C5 - Mar-03-25 07:18AM - Amylyx Pharmaceuticals Inc (AMLX) Q4 2024: Everything You Need To Know Ahead Of Earnings
C6 - Feb-25-25 09:00AM - Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences
C7 - Feb-24-25 09:00AM - Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025
C8 - Feb-10-25 09:00AM - Amylyx Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Amylyx Pharmaceuticals (AMLX)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

AMLX_OUT_3 [2025-04-02 16:25:57 -0400] 1098 Bytes | 311 tokens | Cum: 1010 tkns (12.62% of 8k)
==========================================================================

Showing C2 (chunk 1 of 8): C2:
**Is Amylyx Pharmaceuticals (AMLX) The Hot Biotech Stock Under $5?**
Date: Mar-27-25 10:17AM
Source: (InsiderMonkey)
URL: https://www.insidermonkey.com/blog/is-amylyx-pharmaceuticals-amlx-the-hot-biotech-stock-under-5-1493566

Our #1 AI Stock Pick is on asteep discount- 29.99$ instead of 99.99$!Click hereto access exclusive investment research and ad free browsing!

Our #1 AI Stock Pick is on asteep discount- 29.99$ instead of 99.99$!Click hereto access exclusive research!

We recently published a list of10 Hot Biotech Stocks Under $5. In this article, we are going to take a look at where Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) stands against other hot biotech stocks under $5.

The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing investor attention. After a tough 2024, the industry is ready for major growth powered b

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

AMLX_OUT_5 [2025-04-02 16:25:58 -0400] 990 Bytes | 293 tokens | Cum: 1372 tkns (17.15% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-02T13:00:51Z - Amylyx Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference...
A2 - 2025-03-31T06:20:19Z - Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Average Recommendation of "Moderate Buy" from Br...
A3 - 2025-03-25T20:32:19Z - Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Director Purchases $37,000.00 in Stock...
A4 - 2025-03-25T08:23:31Z - Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Director Acquires $37,000.00 in Stock...
A5 - 2025-03-12T12:51:15Z - Hello Group, loanDepot, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

AMLX_OUT_7 [2025-04-02 16:26:01 -0400] 889 Bytes | 283 tokens | Cum: 1657 tkns (20.71% of 8k)
==========================================================================

Showing A1 (chunk 1 of 1): A1:
**Amylyx Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference**Date: 2025-04-02Source: {'uri': 'eagletribune.com', 'dataType': 'news', 'title': 'Eagle-Tribune'}URL: https://www.eagletribune.com/region/amylyx-pharmaceuticals-to-present-at-the-24th-annual-needham-virtual-healthcare-conference/article_188b78b2-5166-529e-8c04-8ccb513233e7.htmlCAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 2, 2025--

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) ("Amylyx" or the "Company") today announced that management will present at the 24th Annual Needham Virtual Healthcare Conference. The corporate presentation will take place on Wednesday, April 9, 2025, at 8:00 a.m. ET.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

AMLX_OUT_9 [2025-04-02 16:26:01 -0400] 867 Bytes | 284 tokens | Cum: 2014 tkns (25.17% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-10-18T11:26:55Z - Why Amylyx Pharmaceuticals Stock Was So Healthy This Week
B2 - 2024-05-10T18:01:12Z - Breaking Down Amylyx Pharma: 9 Analysts Share Their Views
B3 - 2024-05-09T12:15:07Z - Amylyx Pharmaceuticals, Inc. (AMLX) Reports Q1 Loss, Lags Revenue Estimates
B4 - 2024-04-12T13:22:00Z - The Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals
B5 - 2024-04-10T17:19:00Z - Biotech Stock Roundup: MRNA Up on Vaccine Data, BMY's Updates & More News
B6 - 2024-04-08T12:00:22Z - Unveiling 6 Analyst Insights On Amylyx Pharma

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

AMLX_OUT_11 [2025-04-02 16:26:06 -0400] 809 Bytes | 215 tokens | Cum: 2231 tkns (27.89% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Why Amylyx Pharmaceuticals Stock Was So Healthy This Week**Date: Unknown DateSource: Unknown SourceURL: https://www.fool.com/investing/2024/10/18/why-amylyx-pharmaceuticals-stock-was-so-healthy-th/?source=iedfolrf0000001Amylyx Pharmaceuticals' stock rose over 10% this week after the company reported positive results from a phase 2 clinical trial of its drug AMX0035 for the rare genetic disorder Wolfram Syndrome. The treatment was well-tolerated and showed sustained improvement in pancreatic function, leading the company to plan discussions with the FDA about advancing the drug to phase 3 testing.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

AMLX_OUT_13 [2025-04-02 16:26:07 -0400] 509 Bytes | 119 tokens | Cum: 2428 tkns (30.35% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S10 - 2025-03-04 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper.

The following information should be read in conjunction with the CONS financial information and the notes thereto appearing elsewhere in this Annual Report.

This discussion...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

AMLX_OUT_15 [2025-04-02 16:26:11 -0400] 1099 Bytes | 223 tokens | Cum: 2653 tkns (33.16% of 8k)
==========================================================================

Showing S10 (chunk 1 of 6): S10:
Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations.

The following information should be read in conjunction with the consolidated financial information and the notes thereto appearing elsewhere in this Annual Report.

This discussion and other parts of this Annual Report contain forward-looking statements that involve risks and uncertainties, such as statements of our plans, objectives, expectations and intentions. As a result of many factors, including those factors set forth in the Risk Factors section of this Annual Report, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis .

Overview

We are a clinical-stage pharmaceutical company with a mission to develop novel therapies for communities with high unmet medical need

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

AMLX_OUT_17 [2025-04-02 16:26:20 -0400] 6626 Bytes | 1884 tokens | Cum: 4637 tkns (57.96% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+-----------------------+-------------------------+------------------------+
| Volume: 760,076 | Perf Month: 25.58% | Option/Short: Yes / Yes | Sales Y/Y TTM: -77.06% |
+---------------------+-----------------------+-------------------------+------------------------+
| Avg Volume: 842.38K | Perf Quarter: -1.56% | Short Float: 5.87% | ROE: -100.88% |
+---------------------+-----------------------+-------------------------+------------------------+
| Rel Volume: 0.90 | Index: - | Short Ratio: 4.45 | ROI: -182.62% |
+---------------------+-----------------------+-------------------------+------------------------+
| RSI (14): 53.94 | Market Cap: 334.91M | Short Interest: 3.75M | Sales Surprise: - |
+---------------------+-----------------------+-------------------------+------------------------+
| ATR (14): 0.31 | Shs Outstand: 68.63M | Beta: -0.53 | EPS Surprise: -5.77% |
+---------------------+-----------------------+-------------------------+------------------------+
| SMA20: 2.32% | Shs Float: 63.79M | Sales Q/Q: -100.61% | P/E: - |
+---------------------+-----------------------+-------------------------+------------------------+
| SMA50: 6.59% | Inst Own: 56.45% | Sales past 5Y: 1825.06% | Earnings: Mar 04 BMO |
+---------------------+-----------------------+-------------------------+------------------------+
| SMA200: 10.63% | Insider Own: 28.01% | Employees: 123 | |
+---------------------+-----------------------+-------------------------+------------------------+
| Perf Week: -0.79% | Insider Trans: -0.44% | Debt/Eq: 0.01 | |
+---------------------+-----------------------+-------------------------+------------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: Amylyx Pharmaceuticals, Inc. (AMLX) by Zeiher Bernhardt G (Unknown Title) on 2025-03-20
- Common Stock: 10000 shares at $3.7005 (D)

Inside Trans: Amylyx Pharmaceuticals, Inc. (AMLX) by Mazzariello Gina (Chief Legal Officer) on 2025-03-06
- Common Stock: 63851 shares at $0 (D)
- Stock Option (right to buy): 95777 shares at $0 (D)

Inside Trans: Amylyx Pharmaceuticals, Inc. (AMLX) by Bedrosian Camille L (Chief Medical Officer) on 2025-03-06
- Common Stock: 68420 shares at $0 (D)
- Stock Option (Right to Buy): 102630 shares at $0 (D)

Inside Trans: Amylyx Pharmaceuticals, Inc. (AMLX) by Klee Justin B. (Co-Chief Executive Officer) on 2025-03-06
- Common Stock: 180118 shares at $0 (D)
- Stock Option (right to buy): 270177 shares at $0 (D)

Inside Trans: Amylyx Pharmaceuticals, Inc. (AMLX) by Cohen Joshua B (Co-Chief Executive Officer) on 2025-03-06
- Common Stock: 180118 shares at $0 (D)
- Stock Option (Right to Buy): 270177 shares at $0 (D)

Inside Trans: Amylyx Pharmaceuticals, Inc. (AMLX) by FRATES JAMES M (Chief Financial Officer) on 2025-03-06
- Common Stock: 68420 shares at $0 (D)
- Stock Option (right to buy): 102630 shares at $0 (D)

Inside Trans: Amylyx Pharmaceuticals, Inc. (AMLX) by Mazzariello Gina (Chief Legal Officer) on 2025-03-03
- Common Stock: 1611 shares at $3.1175 (D) Footnote: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

Inside Trans: Amylyx Pharmaceuticals, Inc. (AMLX) by Klee Justin B. (Co-Chief Executive Officer) on 2025-03-03
- Common Stock: 4595 shares at $3.152 (D) Footnote: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

Inside Trans: Amylyx Pharmaceuticals, Inc. (AMLX) by Cohen Joshua B (Co-Chief Executive Officer) on 2025-03-03
- Common Stock: 4595 shares at $3.1663 (D) Footnote: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 87371000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -301743000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 3.78
Average Volume: 871583.04
30-Day High: 3.91
30-Day Low: 3

[Detailed Financials: TTM 2024]
- Total Assets: $193,634,000.0
- Total Liabilities: $28,869,000.0
- Total Equity: $164,765,000.0
- Current Assets: $189,432,000.0
- Current Liabilities: $28,406,000.0

[Income Statement: TTM 2024]
- Revenue: $87,371,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -4.43

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $-92,083,000.0

[Detailed Financials: FY 2024]
- Total Assets: $193,634,000.0
- Total Liabilities: $28,869,000.0
- Total Equity: $164,765,000.0
- Current Assets: $189,432,000.0
- Current Liabilities: $28,406,000.0

[Income Statement: FY 2024]
- Revenue: $87,371,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -4.43

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $-92,083,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

AMLX_OUT_19 [2025-04-02 16:26:21 -0400] 676 Bytes | 167 tokens | Cum: 4994 tkns (62.42% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

AMLX_IN_21 [2025-04-02 16:26:22 -0400] 126 Bytes | 29 tokens | Cum: 5051 tkns (63.14% of 8k)
==========================================================================

====================================
[2025-04-02 16:26:22] # Analysis Completed
Elapsed Time: 29.42 seconds